Skip to content
Open access

Targeting ELF3 with Biomimetic Nanotherapy Sensitizes PDAC to Gemcitabine via GSDME-mediated Pyroptosis.

Nov 2026 · Pharmacological Research · pp. 109749 · 0 citations · 54 references
Medicine

Abstract

Pancreatic ductal adenocarcinoma (PDAC) continues to be a lethal malignancy with limited effective treatment strategies due to modest intrinsic response to systemic chemotherapy. Moreover, the dense, fibrotic stroma and poor vasculature of pancreatic tumors severely restrict drug penetration and therapeutic efficacy. The transcription factor ELF3 acts as a key oncogenic driver that promotes tumor growth, metastasis, and chemoresistance. To address these delivery barriers and enhance therapeutic response, we developed a biomimetic nanoplatform using cancer cell membrane-coated ZIF-8 nanoparticles (CNPs) to co-deliver gemcitabine (GEM) and an ELF3-targeting shRNA (shELF3), aiming to improve tumor-targeting specificity and elucidate the underlying cell death mechanism. Efficient encapsulation of GEM and shRNA ELF3 within a biomimetic nanocarrier was successfully confirmed. In vitro evaluation demonstrated that GEM/shELF3-CNPs activated canonical caspase-3/gasdermin E (GSDME)-dependent pyroptosis, resulting in markedly enhanced cytotoxicity in 6606 PDA cells. Furthermore, in vivo administration yielded superior tumor accumulation, potent tumor growth suppression, and significantly prolonged survival in the murine PDAC model, alongside favorable biosafety profiles. Our findings demonstrate that combining ELF3 silencing with gemcitabine delivery via biomimetic nanocarriers presents a promising synergistic strategy to sensitize pancreatic tumors and enhance PDAC therapeutic outcomes. The graphical representation of the study is shown in Fig. 1.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.